Clinical Trials Logo

Clinical Trial Summary

This study is a randomized, double-blind, placebo-controlled first-in-human study in which the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered HPN-01 will be evaluated in healthy subjects


Clinical Trial Description

This study aims to obtain safety, tolerability, pharmacokinetic and pharmacodynamic data when HPN-01 is orally administered as single doses and as multiple doses to healthy subjects. The study will be conducted in 2 parts: a single ascending dose (SAD) phase (Part 1) and a multiple ascending dose (MAD) phase (Part 2). One cohort of Part 1 will receive HPN-01 after a standard high fat/high calorie breakfast (the fed condition) to investigate the effect of food on the pharmacokinetics of HPN-01. ;


Study Design


Related Conditions & MeSH terms

  • Fatty Liver
  • Non-alcoholic Fatty Liver Disease
  • Non-Alcoholic Steatohepatitis (NASH)

NCT number NCT04481594
Study type Interventional
Source Hepanova Inc.
Contact Michelle Pluviose, MS
Phone 201-416-7763
Email mpluviose@frontagelab.com
Status Recruiting
Phase Phase 1
Start date September 8, 2020
Completion date July 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06151964 - A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese Phase 1/Phase 2
Completed NCT04019561 - A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Phase 2
Completed NCT01694849 - Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) Phase 2
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03517540 - Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis Phase 2
Withdrawn NCT05050721 - Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis
Active, not recruiting NCT04682600 - The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF N/A
Enrolling by invitation NCT01950884 - Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Phase 4
Completed NCT04483947 - A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients Phase 1
Completed NCT02927314 - A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease Phase 2
Active, not recruiting NCT02612662 - A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects Phase 1
Recruiting NCT06168383 - To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) . Phase 2
Terminated NCT02605616 - Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD) Phase 2
Completed NCT02158351 - Gut Microbiota and Modulation of Liver Damage in NAFLD
Recruiting NCT03151473 - Longitudinal Observational Study Of Chinese With NAFLD/NASH
Recruiting NCT04820036 - A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) N/A
Recruiting NCT05553470 - Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant Phase 1
Recruiting NCT04639414 - Combined Active Treatment in Type 2 Diabetes With NASH Phase 4
Withdrawn NCT04607655 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis Phase 1/Phase 2
Recruiting NCT02654665 - Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Phase 3